Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchSelect treatment..Select..
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

 

Efficacy of Ulinastatin in the Treatment of COVID-19: A Retrospective Study

Liu et al., International Journal of General Medicine, doi:10.2147/ijgm.s486434
Dec 2024  
  Post
  Facebook
Share
  Source   PDF  
Retrospective 124 hospitalized COVID-19 patients in China showing higher clinical improvement rate with ulinastatin treatment, particularly with 7 or more days of treatment, and improved lymphocyte counts, but no significant difference in length of hospitalization. There were no adverse events.
Liu et al., 24 Dec 2024, retrospective, China, peer-reviewed, 3 authors, study period 31 December, 2022 - 8 July, 2023. Contact: wuqitjykdxzyy@163.com.
This PaperMiscellaneousAll
Efficacy of Ulinastatin in the Treatment of COVID-19: A Retrospective Study
Peng Liu, Qi Wu, Mengjie Li
International Journal of General Medicine, doi:10.2147/ijgm.s486434
Purpose: This retrospective study aimed to evaluate the efficacy of ulinastatin in the treatment of COVID-19 patients compared to conventional therapy. Patients and Methods: A total of 437 COVID-19 patients admitted to the Respiratory Oncology Department of our hospital between December 31, 2022, and July 8, 2023, were included in the study. Patients were classified into the observation group (n=62) receiving ulinastatin in addition to standard treatment and the control group (n=347) receiving standard treatment only. Clinical information, laboratory results, and treatment outcomes were collected and analyzed. Results: The observation group showed an improvement in lymphocyte count compared to the control group. The clinical improvement rate in patients receiving ulinastatin for 7 days or longer was 92.1%, significantly higher than that of patients treated for less than 7 days (62.5%) and those receiving standard treatment (71.0%). No significant difference in total length of hospitalization was observed between the two groups, and no related adverse events occurred in either group. Conclusion: Ulinastatin treatment improves lymphocyte counts in severe COVID-19 patients, and the clinical improvement rate is significantly higher with treatment duration of 7 days or longer. Larger-scale randomized controlled trials are warranted to further explore the role of ulinastatin in the management of COVID-19.
International Journal of General Medicine Dovepress DovePress International Journal of General Medicine 2024:17
References
Chen, Hu, Liu, Safety and tolerability of high-dose ulinastatin after 2-hour intravenous infusion in adult healthy Chinese volunteers: a randomized, double-blind, placebo-controlled, ascending-dose study, PLoS One, doi:10.1371/journal.pone.0177425
Chen, Wu, Guo, Clinical and immunological features of severe and moderate coronavirus disease 2019, J Clin Invest, doi:10.1172/JCI137244
Commission, Nao, Guideline on diagnosis and treatment of novel coronavirus pneumonia (Trial Version 10), Infectious Dis Inf
Drozdzal, Rosik, Lechowicz, An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment, Drug Resist Updat, doi:10.1016/j.drup.2021.100794
Huang, Hu, Sun, Treatment of patients with Covid-19 with a high dose of ulinastatin, Exp Ther Med, doi:10.3892/etm.2021.11044
Jain, Kasliwal, Jain, Effect of Urinary Trypsin Inhibitor (Ulinastatin) Therapy in COVID-19, Indian J Crit Care Med, doi:10.5005/jp-journals-10071-24156
Jin, Li, Tang, Zou, Chen, Protective effect of Ulinastatin on acute lung injury in diabetic sepsis rats, Int Immunopharmacol, doi:10.1016/j.intimp.2022.108908
Karnad, Bhadade, Verma, Intravenous administration of ulinastatin (human urinary trypsin inhibitor) in severe sepsis: a multicenter randomized controlled study, Intensive Care Med, doi:10.1007/s00134-014-3278-8
Kevadiya, Machhi, Herskovitz, Diagnostics for SARS-CoV-2 infections, Nat Mater, doi:10.1038/s41563-020-00906-z
Lagoo, Mc, Kartha, Kutappa, Role of Ulinastatin, a trypsin inhibitor, in severe acute pancreatitis in critical care setting: a retrospective analysis, J Crit Care, doi:10.1016/j.jcrc.2018.01.021
Liu, Li, Liu, Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients, EBioMedicine, doi:10.1016/j.ebiom.2020.102763
Mehta, Dixit, Zirpe, Ansari, Cytokine Storm in Novel Coronavirus Disease (COVID-19): expert Management Considerations, Indian J Crit Care Med, doi:10.5005/jp-journals-10071-23415
Mehta, Zirpe, Dixit, Ulinastatin Add-on to Standard of Care in Critically Ill COVID-19 Patients: a Multicenter, Retrospective Study, J Assoc Physicians India, doi:10.5005/japi-11001-0181
Moorthy, Gaikwad, Krishna, SARS-CoV-2, Uncontrolled Diabetes and Corticosteroids-An Unholy Trinity in Invasive Fungal Infections of the Maxillofacial Region? A Retrospective, Multi-centric Analysis, J Maxillofac Oral Surg, doi:10.1007/s12663-021-01532-1
Palladino, Complete blood count alterations in COVID-19 patients: a narrative review, Biochem Med, doi:10.11613/BM.2021.030501
Qiao, Guo, Huang, Zhang, Li et al., Expression of Angiopoietin-2 in Lung Tissue of Juvenile SD Rats with Lipopolysaccharide-Induced Acute Lung Injury and the Role of Ulinastatin, Arch Immunol Ther Exp (Warsz), doi:10.1007/s00005-023-00688-7
Qs, Lx, Clinical study of UTI combined with non-invasive ventilation in the treatment of acute respiratory distress syndrome, Chin J Clin Pharmacol Res
Sette, Crotty, Adaptive immunity to SARS-CoV-2 and COVID-19, Cell, doi:10.1016/j.cell.2021.01.007
Singh, Singh, Joshi, Misra, Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India, Diabetes Metab Syndr, doi:10.1016/j.dsx.2021.05.019
Tali, Leblanc, Sadiq, Tools and Techniques for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)/ COVID-19 Detection, Clin Microbiol Rev, doi:10.1128/CMR.00228-20
Wang, Liu, Tang, Improvement of Sepsis Prognosis by Ulinastatin: a Systematic Review and Meta-Analysis of Randomized Controlled Trials, Front Pharmacol, doi:10.3389/fphar.2019.01370
Xu, Yan, Chen, Ulinastatin is effective in reducing mortality for critically ill patients with sepsis: a causal mediation analysis, Sci Rep, doi:10.1038/s41598-018-32533-9
Yuan, Jiao, Qu, Yang, Liu, The development of COVID-19 treatment, Front Immunol, doi:10.3389/fimmu.2023.1125246
Zhang, Zhu, Jiao, Liu, Liu et al., Ulinastatin treatment for acute respiratory distress syndrome in China: a meta-analysis of randomized controlled trials, BMC Pulm Med, doi:10.1186/s12890-019-0968-6
Zx, The impact of Ulinastatin injection in patients′ plasma levels of CRP, PCT and lactate in ARDS patients with severe sepsis, J Pract Med
{ 'indexed': { 'date-parts': [[2024, 12, 23]], 'date-time': '2024-12-23T12:40:10Z', 'timestamp': 1734957610563, 'version': '3.32.0'}, 'reference-count': 26, 'publisher': 'Informa UK Limited', 'license': [ { 'start': { 'date-parts': [[2024, 12, 1]], 'date-time': '2024-12-01T00:00:00Z', 'timestamp': 1733011200000}, 'content-version': 'unspecified', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by-nc/3.0/'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'DOI': '10.2147/ijgm.s486434', 'type': 'journal-article', 'created': { 'date-parts': [[2024, 12, 23]], 'date-time': '2024-12-23T12:05:12Z', 'timestamp': 1734955512000}, 'page': '6421-6430', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Efficacy of Ulinastatin in the Treatment of COVID-19: A Retrospective Study', 'prefix': '10.2147', 'volume': 'Volume 17', 'author': [ {'given': 'Peng', 'family': 'Liu', 'sequence': 'first', 'affiliation': []}, {'given': 'Qi', 'family': 'Wu', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mengjie', 'family': 'Li', 'sequence': 'additional', 'affiliation': []}], 'member': '301', 'published-online': {'date-parts': [[2024, 12]]}, 'reference': [ { 'key': 'ref1', 'unstructured': 'WHO Coronavirus (COVID-19) Dashboard [Internet]. Available from: ' 'https://covid19.who.int. Accessed December 9, 2024'}, { 'key': 'ref2', 'doi-asserted-by': 'publisher', 'first-page': '861', 'DOI': '10.1016/j.cell.2021.01.007', 'volume': '184', 'author': 'Sette', 'year': '2021', 'journal-title': 'Cell'}, { 'key': 'ref3', 'doi-asserted-by': 'publisher', 'first-page': '593', 'DOI': '10.1038/s41563-020-00906-z', 'volume': '20', 'author': 'Kevadiya', 'year': '2021', 'journal-title': 'Nat Mater'}, { 'key': 'ref4', 'doi-asserted-by': 'publisher', 'DOI': '10.1128/CMR.00228-20', 'volume': '34', 'author': 'Safiabadi Tali', 'year': '2021', 'journal-title': 'Clin Microbiol Rev'}, { 'key': 'ref5', 'doi-asserted-by': 'publisher', 'first-page': '1125246', 'DOI': '10.3389/fimmu.2023.1125246', 'volume': '14', 'author': 'Yuan', 'year': '2023', 'journal-title': 'Front Immunol'}, { 'key': 'ref6', 'doi-asserted-by': 'publisher', 'first-page': '100794', 'DOI': '10.1016/j.drup.2021.100794', 'volume': '59', 'author': 'Drozdzal', 'year': '2021', 'journal-title': 'Drug Resist Updat'}, { 'key': 'ref7', 'doi-asserted-by': 'publisher', 'first-page': '2620', 'DOI': '10.1172/JCI137244', 'volume': '130', 'author': 'Chen', 'year': '2020', 'journal-title': 'J Clin Invest'}, { 'key': 'ref8', 'doi-asserted-by': 'publisher', 'first-page': '196', 'DOI': '10.1186/s12890-019-0968-6', 'volume': '19', 'author': 'Zhang', 'year': '2019', 'journal-title': 'BMC Pulm Med'}, { 'key': 'ref9', 'doi-asserted-by': 'publisher', 'first-page': '1370', 'DOI': '10.3389/fphar.2019.01370', 'volume': '10', 'author': 'Wang', 'year': '2019', 'journal-title': 'Front Pharmacol'}, { 'key': 'ref10', 'doi-asserted-by': 'publisher', 'first-page': '23', 'DOI': '10.1007/s00005-023-00688-7', 'volume': '71', 'author': 'Qiao', 'year': '2023', 'journal-title': 'Arch Immunol Ther Exp (Warsz)'}, { 'key': 'ref11', 'doi-asserted-by': 'publisher', 'first-page': '108908', 'DOI': '10.1016/j.intimp.2022.108908', 'volume': '108', 'author': 'Jin', 'year': '2022', 'journal-title': 'Int Immunopharmacol'}, { 'key': 'ref12', 'doi-asserted-by': 'publisher', 'first-page': '429', 'DOI': '10.5005/jp-journals-10071-23415', 'volume': '24', 'author': 'Mehta', 'year': '2020', 'journal-title': 'Indian J Crit Care Med'}, { 'key': 'ref13', 'doi-asserted-by': 'publisher', 'first-page': '11', 'DOI': '10.5005/japi-11001-0181', 'volume': '71', 'author': 'Mehta', 'year': '2023', 'journal-title': 'J Assoc Physicians India'}, { 'key': 'ref14', 'doi-asserted-by': 'publisher', 'first-page': '696', 'DOI': '10.5005/jp-journals-10071-24156', 'volume': '26', 'author': 'Jain', 'year': '2022', 'journal-title': 'Indian J Crit Care Med'}, { 'key': 'ref15', 'first-page': '18', 'volume': '36', 'author': 'Commission', 'year': '2023', 'journal-title': 'Infectious Dis Inf'}, { 'key': 'ref16', 'doi-asserted-by': 'publisher', 'first-page': '121', 'DOI': '10.3892/etm.2021.11044', 'volume': '23', 'author': 'Huang', 'year': '2022', 'journal-title': 'Exp Ther Med'}, { 'key': 'ref17', 'doi-asserted-by': 'publisher', 'first-page': '418', 'DOI': '10.1007/s12663-021-01532-1', 'volume': '20', 'author': 'Moorthy', 'year': '2021', 'journal-title': 'J Maxillofac Oral Surg'}, { 'key': 'ref18', 'doi-asserted-by': 'publisher', 'first-page': '102146', 'DOI': '10.1016/j.dsx.2021.05.019', 'volume': '15', 'author': 'Singh', 'year': '2021', 'journal-title': 'Diabetes Metab Syndr'}, { 'key': 'ref19', 'doi-asserted-by': 'publisher', 'first-page': 'e0177425', 'DOI': '10.1371/journal.pone.0177425', 'volume': '12', 'author': 'Chen', 'year': '2017', 'journal-title': 'PLoS One'}, { 'key': 'ref20', 'doi-asserted-by': 'publisher', 'first-page': '14360', 'DOI': '10.1038/s41598-018-32533-9', 'volume': '8', 'author': 'Xu', 'year': '2018', 'journal-title': 'Sci Rep'}, { 'key': 'ref21', 'doi-asserted-by': 'publisher', 'first-page': '830', 'DOI': '10.1007/s00134-014-3278-8', 'volume': '40', 'author': 'Karnad', 'year': '2014', 'journal-title': 'Intensive Care Med'}, { 'key': 'ref22', 'doi-asserted-by': 'publisher', 'first-page': '27', 'DOI': '10.1016/j.jcrc.2018.01.021', 'volume': '45', 'author': 'Lagoo', 'year': '2018', 'journal-title': 'J Crit Care'}, { 'key': 'ref23', 'doi-asserted-by': 'publisher', 'first-page': '102763', 'DOI': '10.1016/j.ebiom.2020.102763', 'volume': '55', 'author': 'Liu', 'year': '2020', 'journal-title': 'EBioMedicine'}, { 'key': 'ref24', 'doi-asserted-by': 'publisher', 'first-page': '030501', 'DOI': '10.11613/BM.2021.030501', 'volume': '31', 'author': 'Palladino', 'year': '2021', 'journal-title': 'Biochem Med (Zagreb)'}, { 'key': 'ref25', 'first-page': '1268', 'volume': '32', 'author': 'QS', 'year': '2016', 'journal-title': 'Chin J Clin Pharmacol Res'}, { 'key': 'ref26', 'first-page': '1692', 'volume': '31', 'author': 'ZX', 'year': '2015', 'journal-title': 'J Pract Med'}], 'container-title': 'International Journal of General Medicine', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://www.dovepress.com/article/download/98679', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://www.dovepress.com/article/download/98679', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2024, 12, 23]], 'date-time': '2024-12-23T12:05:16Z', 'timestamp': 1734955516000}, 'score': 1, 'resource': { 'primary': { 'URL': 'https://www.dovepress.com/efficacy-of-ulinastatin-in-the-treatment-of-covid-19-a-retrospective-s-peer-reviewed-fulltext-article-IJGM'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2024, 12]]}, 'references-count': 26, 'URL': 'http://dx.doi.org/10.2147/ijgm.s486434', 'relation': {}, 'ISSN': ['1178-7074'], 'subject': [], 'container-title-short': 'IJGM', 'published': {'date-parts': [[2024, 12]]}}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit